Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriers

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by synovitis, systemic inflammation and autoantibodies, leading to joint damage and disability. RA pathogenesis is characterized by a dysregulated interaction between immune cells, particularly B cells and T cells, which releas...

Descripción completa

Detalles Bibliográficos
Autores: Fernández Alarcón, Jennifer, Karusan, Nisha Rata, Presciutti, Clara, Miras, Jonathan, Magana, José Rodrigo, Guerra-Rebollo, Marta, Borrós, Salvador, Ahmad, Noraini, Fornaguera, Cristina
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/397525
Acceso en línea:http://hdl.handle.net/10261/397525
https://api.elsevier.com/content/abstract/scopus_id/105012305286
Access Level:acceso abierto
Palabra clave:Rheumatoid arthritis therapy
Lipid neurocarriers
http://metadata.un.org/sdg/3
Ensure healthy lives and promote well-being for all at all ages
id ES_aadea876e10814daf0e003ae40be8917
oai_identifier_str oai:digital.csic.es:10261/397525
network_acronym_str ES
network_name_str España
repository_id_str
spelling Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriersFernández Alarcón, JenniferKarusan, Nisha RataPresciutti, ClaraMiras, JonathanMagana, José RodrigoGuerra-Rebollo, MartaBorrós, SalvadorAhmad, NorainiFornaguera, CristinaRheumatoid arthritis therapyLipid neurocarriershttp://metadata.un.org/sdg/3Ensure healthy lives and promote well-being for all at all agesRheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by synovitis, systemic inflammation and autoantibodies, leading to joint damage and disability. RA pathogenesis is characterized by a dysregulated interaction between immune cells, particularly B cells and T cells, which release inflammatory cytokines. This review explores the pivotal role of these immune cells in sustaining the inflammatory response and contributing to tissue injury. We provide a comprehensive overview of current RA therapies, highlighting the limitations of conventional treatments and the pressing need for targeted drug delivery systems such as lipid nanocarrier-based therapies, including nano-emulsions, solid lipid nanoparticles (SLNs), niosomes, liposomes, transferosomes, and ethosomes. Emphasizing niosomes, we discuss their capacity to encapsulate multiple drugs, significantly enhancing bioavailability and therapeutic efficacy. By directing drug-loaded niosomes to inflamed synovial sites, this innovative approach minimizes systemic side effects while maximizing localized drug concentrations, thereby optimizing treatment outcomes for RA patients. This review underscores the importance of targeted (nano)drug delivery in improving patient's life quality and represents a significant step toward more effective, personalized RA therapies by deepening our understanding of the underlying mechanisms.Authors gratefully acknowledge the Institut Químic de Sarrià (IQS), Ramon Llull University (URL) for the research financial support under the project PID2021-125910OB-I00 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE and the Universiti Malaya (UM) for the financial support through the UM Research Fund Assistance (BKP Special) (BKS001-2024). CF acknowledges the support of the Departament de Recerca i Universitats of the Generalitat de Catalunya through the ICREA Acadèmia 2024 programme. Figures were created using Biorender.Peer reviewedRoyal Society of Chemistry (UK)Ministerio de Ciencia e Innovación (España)0000-0002-4003-03810000-0002-1174-47480000-0002-7014-3213Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202520252025info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/397525https://api.elsevier.com/content/abstract/scopus_id/105012305286reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/MCIN/AEI/10.13039RSC advanceshttps://doi.org/10.1039/D5RA04258ESíinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3975252026-05-22T06:33:51Z
dc.title.none.fl_str_mv Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriers
title Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriers
spellingShingle Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriers
Fernández Alarcón, Jennifer
Rheumatoid arthritis therapy
Lipid neurocarriers
http://metadata.un.org/sdg/3
Ensure healthy lives and promote well-being for all at all ages
title_short Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriers
title_full Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriers
title_fullStr Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriers
title_full_unstemmed Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriers
title_sort Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriers
dc.creator.none.fl_str_mv Fernández Alarcón, Jennifer
Karusan, Nisha Rata
Presciutti, Clara
Miras, Jonathan
Magana, José Rodrigo
Guerra-Rebollo, Marta
Borrós, Salvador
Ahmad, Noraini
Fornaguera, Cristina
author Fernández Alarcón, Jennifer
author_facet Fernández Alarcón, Jennifer
Karusan, Nisha Rata
Presciutti, Clara
Miras, Jonathan
Magana, José Rodrigo
Guerra-Rebollo, Marta
Borrós, Salvador
Ahmad, Noraini
Fornaguera, Cristina
author_role author
author2 Karusan, Nisha Rata
Presciutti, Clara
Miras, Jonathan
Magana, José Rodrigo
Guerra-Rebollo, Marta
Borrós, Salvador
Ahmad, Noraini
Fornaguera, Cristina
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Ciencia e Innovación (España)
0000-0002-4003-0381
0000-0002-1174-4748
0000-0002-7014-3213
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Rheumatoid arthritis therapy
Lipid neurocarriers
http://metadata.un.org/sdg/3
Ensure healthy lives and promote well-being for all at all ages
topic Rheumatoid arthritis therapy
Lipid neurocarriers
http://metadata.un.org/sdg/3
Ensure healthy lives and promote well-being for all at all ages
description Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by synovitis, systemic inflammation and autoantibodies, leading to joint damage and disability. RA pathogenesis is characterized by a dysregulated interaction between immune cells, particularly B cells and T cells, which release inflammatory cytokines. This review explores the pivotal role of these immune cells in sustaining the inflammatory response and contributing to tissue injury. We provide a comprehensive overview of current RA therapies, highlighting the limitations of conventional treatments and the pressing need for targeted drug delivery systems such as lipid nanocarrier-based therapies, including nano-emulsions, solid lipid nanoparticles (SLNs), niosomes, liposomes, transferosomes, and ethosomes. Emphasizing niosomes, we discuss their capacity to encapsulate multiple drugs, significantly enhancing bioavailability and therapeutic efficacy. By directing drug-loaded niosomes to inflamed synovial sites, this innovative approach minimizes systemic side effects while maximizing localized drug concentrations, thereby optimizing treatment outcomes for RA patients. This review underscores the importance of targeted (nano)drug delivery in improving patient's life quality and represents a significant step toward more effective, personalized RA therapies by deepening our understanding of the underlying mechanisms.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/397525
https://api.elsevier.com/content/abstract/scopus_id/105012305286
url http://hdl.handle.net/10261/397525
https://api.elsevier.com/content/abstract/scopus_id/105012305286
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/MCIN/AEI/10.13039
RSC advances
https://doi.org/10.1039/D5RA04258E
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Royal Society of Chemistry (UK)
publisher.none.fl_str_mv Royal Society of Chemistry (UK)
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416218849443840
score 15,811543

Similares en LA Referencia